# A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

> **NCT03412006** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 152 (actual)

## Conditions studied

- Diabetic Kidney Disease

## Interventions

- **DRUG:** Fulacimstat (BAY1142524)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03412006
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-02
- **Primary completion:** 2019-10-02
- **Final completion:** 2019-10-10
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412006, "A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03412006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*